A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.

NAActive, not recruitingINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

December 24, 2020

Primary Completion Date

January 24, 2029

Study Completion Date

April 24, 2029

Conditions
Late EffectsTesticular Germ Cell Tumor MixedNon-Metastatic Breast CarcinomaSoft Tissue Sarcoma, Adult, Stage IICOsteosarcomaEwing's SarcomaAcute Myeloid LeukemiaHodgkin DiseaseNon Hodgkin Lymphoma
Interventions
OTHER

PASCA intervention

"At each study visit (T1 = 1 month, T2 = 6 months, T3 = 24 months, T4 = 60 months), an exhaustive screening of complications as well as associated sub-clinical abnormalities and risk factors previously identified as such in the literature, will be conducted.~Management of complications consists of referring the patient to a healthcare professional belonging to the PASCA network based on the test results. Referral is defined by referring to pre-established decision trees. It is made to a specialist physician, a health professional from the paramedical field or the patient's general practitioner who confirms the diagnosis if necessary and initiates the patient's care and follow-up. These patients also receive their usual follow-up in the context of their tumor pathology in oncology and onco-hematology."

Trial Locations (1)

69373

Centre Leon Berard, Lyon

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Malakoff-Humanis

UNKNOWN

collaborator

Fondation Apicil

OTHER

collaborator

Fédération Leucémie Espoir

UNKNOWN

collaborator

Biogaran

UNKNOWN

collaborator

Le défi Anthony

UNKNOWN

collaborator

Novartis

INDUSTRY

collaborator

Roche Pharma AG

INDUSTRY

lead

Centre Leon Berard

OTHER